

1. Nishizaki M, Ogawa A, Matsubara H. High Right Ventricular Afterload during Exercise in Patients with Pulmonary Arterial Hypertension. *J Clin Med*. 10(9); 2024. 2021.
2. Shimokawahara H, Nagayoshi S, Ogawa A, Matsubara H. Continual Improvement in Pressure Gradient at the Lesion after Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. *Can J Cardiol*. S0828-282X(21); 00158-6. 2021.
3. Dan K, Shionoda A, Matsubara H. Systematic Staged Percutaneous Balloon Pulmonary Angioplasty in Severe Inoperable Chronic Thromboembolic Pulmonary Hypertension. *Arq Bras Cardiol*. 116(2 suppl 1); 21-24. 2021.
4. Nishizaki M, Ogawa A, Matsubara H. Response to exercise in patients with pulmonary arterial hypertension treated with combination therapy. *ERJ Open Res*. 7(1); 00725-2020. 2021.
5. Tamura Y, Kumamaru H, Abe K, Satoh T, Miyata H, Ogawa A, Tanabe N, Hatano M, Yao A, Tsujino I, Fukuda K, Kimura H, Kuwana M, Matsubara H, Tatsumi K; Japan Pulmonary Hypertension Registry (JAPHR) Network. Improvements in French risk stratification score were correlated with reductions in mean pulmonary artery pressure in pulmonary arterial hypertension: a subanalysis of the Japan Pulmonary Hypertension Registry (JAPHR). *BMC Pulm Med*. 21(1); 28. 2021.
6. Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok FA, Lang I, Jenkins D, Kim NH, Humbert M, Jais X, Noordegraaf AV, Pepke-Zaba J, Brénot P, Dorfmueller P, Fadel E, Ghofrani HA, Hoeper MM, Jansa P, Madani M, Matsubara H, Ogo T, Grünig E, D'Armini A, Galie N, Meyer B, Corkery P, Meszaros G, Mayer E, Simonneau G. ERS Statement on Chronic Thromboembolic Pulmonary Hypertension. *Eur Respir J*. 2002828. 2020.
7. Wada H, Suzuki M, Matsuda M, Ajiro Y, Shinozaki T, Sakagami S, Yonezawa K, Shimizu M, Funada J, Takenaka T, Morita Y, Nakamura T, Fujimoto K, Matsubara H, Kato T, Unoki T, Takagi D, Wada K, Wada M, Iguchi M, Masunaga N, Ishii M, Yamakage H, Kusakabe T, Yasoda A, Shimatsu A, Kotani K, Satoh-Asahara N, Abe M, Akao M, Hasegawa K; ANOX Study Investigators. Impact of Smoking Status on Growth Differentiation Factor 15 and Mortality in Patients With Suspected or Known Coronary Artery Disease: The ANOX Study. *J Am Heart Assoc*. 9(22); e018217. 2020.
8. Tanabe N, Fukuda K, Matsubara H, Nakanishi N, Tahara N, Ikeda S, Kishi T, Satoh T, Hirata KI, Inoue T, Kimura H, Okano Y, Okazaki O, Sata M, Tsujino I, Ueno S,

Yamada N, Yao A, Kuriyama T. Selexipag for Chronic Thromboembolic Pulmonary Hypertension in Japanese Patients - A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase II Study. *Circ J.* 84(10); 1866-1874. 2020.

9. Ogawa A, Matsubara H. Increased levels of platelet-derived microparticles in pulmonary hypertension. *Thromb Res.* 195; 120-124. 2020.

10. Morii C, Tanaka HY, Izushi Y, Nakao N, Yamamoto M, Matsubara H, Kano MR, Ogawa A. 3D in vitro Model of Vascular Medial Thickening in Pulmonary Arterial Hypertension. *Front Bioeng Biotechnol.* 8; 482. 2020.

11. Wada H, Suzuki M, Matsuda M, Ajiro Y, Shinozaki T, Sakagami S, Yonezawa K, Shimizu M, Funada J, Takenaka T, Morita Y, Nakamura T, Fujimoto K, Matsubara H, Kato T, Unoki T, Takagi D, Wada K, Wada M, Iguchi M, Masunaga N, Ishii M, Yamakage H, Kusakabe T, Yasoda A, Shimatsu A, Kotani K, Satoh-Asahara N, Abe M, Akao M, Hasegawa K; ANOX Study Investigators. Distinct Characteristics of VEGF-D and VEGF-C to Predict Mortality in Patients With Suspected or Known Coronary Artery Disease. *J Am Heart Assoc.* 9(9); e015761. 2020.

12. Ogawa A, Matsubara H. Should oral combination therapy be the standard of care for pulmonary arterial hypertension?

*Expert Rev Respir Med.* 14(4); 341-343. 2020.